Are you ready to use non-invasive testing to unlock the potential in metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) management?
Join the featured speakers for this webinar that will transform your understanding of non-invasive diagnostic tests. This session offers an unparalleled opportunity to delve into the latest advancements, with expert insights from pivotal MASLD/MASH clinical trials, including the ESSENCE and SYMMETRY trials, as well as key longitudinal studies. Reserve your spot today!
MASLD/MASH is a condition marked by the accumulation of fat in the liver, which can progress to more serious liver aliments including fibrosis, cirrhosis and hepatocellular carcinoma. The increasing prevalence of liver diseases worldwide necessitates the development of effective, non-invasive diagnostic techniques.
Diagnosis of MASLD/MASH can be challenging due to its subtle early symptoms and the invasiveness of traditional diagnostic techniques such as biopsies. Recent advancements in non-invasive tests offer promising alternatives for more accessible and accurate diagnosis, which are crucial for timely treatment and management.
This webinar will focus on the latest advancements and findings in non-invasive diagnostic methods for MASLD/MASH as well as insights gained from the ESSENCE/SYMMETRY trials and groundbreaking longitudinal studies.
Monitoring liver stiffness is important for assessing the progression and the future risk of liver-related events in patients with MASH. Vibration-controlled transient elastography (VCTE) has emerged as a valuable non-invasive tool for measuring liver stiffness. Increases and decreases in liver stiffness measurements may be independently associated with the risk of liver-related events in MASLD/MASH.
Elevated liver stiffness indicates the presence of fibrosis, which is a critical marker for predicting adverse liver outcomes. Conversely, a decrease in liver stiffness may suggest improvement in liver health, potentially due to lifestyle changes and/or therapeutic interventions. Both single and serial measurements of VCTE-based scores may play an important role in early detection, risk stratification, monitoring treatment response and guiding clinical decisions. Join the speakers to explore how VCTE impacts MASLD/MASH management and the liver disease burden.
The ESSENCE trial represents a significant step forward in non-invasive diagnostics for MASH, with a discussion on the clinical implications of these findings. As non-invasive tests for MASH become increasingly reliable and widespread, they have the potential to transform the approach in the diagnosis and management of MASLD/MASH.
Register for this webinar to stay ahead in the field of liver disease management. This webinar promises to be a valuable experience for healthcare professionals, researchers and anyone interested in the advancements of MASLD/MASH clinical trials. We invite you to join the speakers as they explore these groundbreaking insights and discuss their implications for the future of healthcare.
Speakers
Naim Alkhouri, MD, Chief Academic Officer, Summit Clinical Research
Naim Alkhouri, MD, is the Chief Academic Officer at Summit Clinical Research, the Director of the SLD program at the Clinical Research Institute of Ohio and the Director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland, OH.
Prior to joining Summit, Dr. Alkhouri served as the Chief Medical Officer and Director of the Steatotic Liver Disease program at Arizona Liver Health in Phoenix, AZ.
Dr. Alkhouri is a key opinion leader in the field of MASH therapeutics and an advisor/consultant to many pharmaceutical and biomarker development companies. He is the Principal Investigator on several multicenter global MASH trials and a member of the AASLD MASLD Special Interest Group (MASLD SIG).
Dr. Alkhouri has been published in over 260 publications, including publications in The New England Journal of Medicine, The Lancet, JAMA, Nature Medicine, Gastroenterology, Hepatology and Journal of Hepatology. He presents his work at both national and international medical conferences.
Message Presenter
Dr. Mazen Noureddin, Chief Scientific Officer, Summit Clinical Research
Mazen Noureddin, MD, MHSc, is the Chief Scientific Officer and Co-Chairman of the board at Summit Clinical Research and Pinnacle Clinical Research.
Dr. Noureddin is internationally known for his research in the area of MASLD/MASH and cirrhosis. He is a Professor of Medicine at the Lynda K. and David M. Underwood Center for Digestive Disorders, the J.C. Walter Jr. Transplant Center, and the Sherrie & Alan Conover Center for Liver Disease & Transplantation at Houston Methodist Hospital (ranked #5 in GI and GI surgery by US News). He has also established the Houston Research Institute, which is a state-of-the-art facility that offers patients with liver disease access to new, innovative, non-invasive diagnostic tests and breakthrough therapies. Prior to his work in Houston, Dr. Noureddin held roles at Cedars-Sinai, UCSD and NIH.
Dr. Noureddin has been published in over 280 publications and presents his work at national and international medical conferences.
Message Presenter
Samer Gawrieh, MD, Professor of Clinical Medicine, Indiana University School of Medicine
Dr. Gawrieh is a Professor of Clinical Medicine and the Director of the Hepatology Research Fellowship Program in the Division of Gastroenterology and Hepatology at Indiana University School of Medicine.
His clinical and translational research focuses on different aspects of steatotic liver disease (metabolic dysfunction- and alcohol-related). His research investigated genetic modifiers of disease risk and severity, disease histological phenotyping with machine learning/artificial intelligence, non-invasive testing and therapeutics in different patient populations, including those of the parent NASH CRN, HIV-NASH CRN and NIAAA-sponsored consortia for alcohol-associated hepatitis.
Dr. Gawrieh serves as the Clinical Director of the Data Coordinating Center for the NIAAA-funded AlcHepNet, a national network of six academic centers in the US that studies different aspects and therapeutics of alcohol-associated hepatitis.
Message PresenterWho Should Attend?
This webinar will appeal to attendees from:
- Pharma companies
- Biotech companies
- Researchers
- Healthcare professionals (i.e., primary care, endocrinologists, hepatologists and gastroenterologists) with a focus on the field of hepatology
What You Will Learn
Attendees will:
- Discover how VCTE is advancing MASLD/MASH management and reducing the liver disease burden
- Understand the ESSENCE/SYMMETRY trials and other longitudinal studies and how they highlight significant progress in non-invasive diagnostics for MASLD/MASH
- Obtain valuable knowledge on how the findings from non-invasive tests can be applied in clinical practice, enhancing the ability to make informed decisions
Xtalks Partner
Summit Clinical Research
Summit Clinical Research is an Integrated Research Organization founded in 2018 to advance clinical trial execution. Launched by Dr. Stephen Harrison and Gail Hinkson, they developed a proven model for overcoming the challenges of MASH research. With a vision to help research sites implement efficient processes and mentor principal investigators (PIs) and research staff on the intricacies of MASH protocols, they established Summit Clinical Research. Together, Summit and our expanding network of sites operate as an Integrated Research Organization, employing effective research strategies and logistical expertise to conduct high-quality studies – managing large patient volumes in MASH, MetALD, ALD, Cirrhosis, Phase I Hepatic Impairment, and Obesity without compromising data integrity. We are led by a team of industry experts and fueled by a passion for advancing medical science. Our network of research sites has grown from the initial fifteen locations to over 100 sites across nine countries, and we remain committed to guiding research sites to new levels of efficiency and effectiveness.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account